Immunotherapy最新文献_第4页

The skin microbiome-immune-barrier axis: implications for inflammatory skin disorders and immunotherapeutic strategies. 皮肤微生物-免疫屏障轴：炎症性皮肤疾病和免疫治疗策略的含义。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-06 DOI: 10.1080/1750743X.2026.2697682

Shreyashree Mohanty, Pratikeswar Panda, Rajaram Mohapatra

{"title":"The skin microbiome-immune-barrier axis: implications for inflammatory skin disorders and immunotherapeutic strategies.","authors":"Shreyashree Mohanty, Pratikeswar Panda, Rajaram Mohapatra","doi":"10.1080/1750743X.2026.2697682","DOIUrl":"10.1080/1750743X.2026.2697682","url":null,"abstract":"The skin microbiome is a complex and dynamic ecosystem that plays a pivotal role in maintaining skin barrier integrity and immune homeostasis. This review provides a comprehensive synthesis of current knowledge on the composition, diversity, and functional significance of the skin microbiota, with particular emphasis on site-specific and temporal variations, as well as intrinsic and extrinsic factors influencing microbial balance. Relevant literature was identified through comprehensive searches of PubMed, Scopus, Web of Science, and Google Scholar databases covering publications from 2018 to 2026. We discuss the multilayered architecture of the skin barrier, encompassing chemical, physical, microbial, and adaptive immune components, and highlight how commensal microorganisms contribute to barrier maintenance, lipid homeostasis, immune modulation, and colonization resistance against pathogens. Dysbiosis of the skin microbiome is critically examined in common dermatological disorders, including wound infections, atopic dermatitis, acne, and psoriasis, where microbial imbalance is closely linked to inflammation and disease progression. This review further explores emerging microbiome-targeted therapeutic strategies aimed at restoring microbial equilibrium and strengthening skin barrier function. Emerging therapies including bacteriotherapy, probiotics, phage therapy, and microbiome transplantation show promise, while challenges involving safety, ethics, and clinical translation remain important considerations.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"715-742"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aflibercept with and without laser therapy in diabetic macular edema: a systematic review and meta-analysis. 阿非利西普联合和不联合激光治疗糖尿病黄斑水肿：一项系统综述和荟萃分析。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-09 DOI: 10.1080/1750743X.2026.2700923

Muhammad Noman Khan, Shamal Khan, Humam Shah, Zeeshan Shah, Muhammad Umair Bukhari, Eman Khalid, Iftikhar Ahmad

{"title":"Aflibercept with and without laser therapy in diabetic macular edema: a systematic review and meta-analysis.","authors":"Muhammad Noman Khan, Shamal Khan, Humam Shah, Zeeshan Shah, Muhammad Umair Bukhari, Eman Khalid, Iftikhar Ahmad","doi":"10.1080/1750743X.2026.2700923","DOIUrl":"10.1080/1750743X.2026.2700923","url":null,"abstract":"Background: Diabetic macular edema (DME) causes visual impairment in diabetic patients. Aflibercept is a standard treatment of DME; however, the benefit of combining it with laser therapy remains uncertain.Methods: A systematic review of randomized controlled trials (RCTs) comparing aflibercept alone with a combination of aflibercept plus laser therapy for management of DME was conducted. PubMed, Cochrane Library, and Embase were searched according to PRISMA guidelines. Primary outcomes were best corrected visual acuity (BCVA) and central macular thickness (CMT), while secondary outcome was treatment burden.Results: Six RCTs involving 275 patients were included. At 12 months, combination therapy yielded a modest improvement in BCVA (mean difference [MD] = 0.18; 95% CI: -0.17 to 0.52; p = 0.32) and a minor reduction in CMT (MD = 0.13 μm; 95% CI: -0.13 to 0.39; p = 0.32). The number of aflibercept injections was slightly lower in the combination group (MD = -0.53 injections; 95% CI: -1.23 to 0.17; p = 0.14).Conclusions: The adjunctive use of laser therapy with aflibercept in DME does not provide statistically significant improvement in visual or anatomical outcomes over aflibercept alone.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"665-675"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy. 消化系统肿瘤的抗tigit治疗：从免疫逃避到精准免疫治疗。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-06-29 DOI: 10.1080/1750743X.2026.2692829

Marianne Matar, Céline Yaghi, Gilles Prince, Houssam El Masri, Hampig Kourie

{"title":"Anti-TIGIT therapies in digestive cancers: from immune evasion to precision immunotherapy.","authors":"Marianne Matar, Céline Yaghi, Gilles Prince, Houssam El Masri, Hampig Kourie","doi":"10.1080/1750743X.2026.2692829","DOIUrl":"10.1080/1750743X.2026.2692829","url":null,"abstract":"Introduction: Immune checkpoint inhibitors, particularly anti-PD-1 and anti-PD-L1 therapies, have transformed cancer treatment, yet their effectiveness in gastrointestinal cancers remains limited due to tumor complexity, immunosuppressive microenvironments, and resistance mechanisms. TIGIT, an emerging immune checkpoint receptor expressed on T cells and natural killer cells, plays a central role in suppressing antitumor immunity by promoting T-cell exhaustion and facilitating tumor immune evasion.Methods: We performed a comprehensive review of preclinical and clinical evidence evaluating anti-TIGIT strategies in GI cancers. Databases and clinical trial registries were searched for studies investigating anti-TIGIT agents as monotherapy or combined with ICIs, chemotherapy, or radiotherapy.Results: Preclinical studies demonstrate that TIGIT blockade restores antitumor immune responses, improves tumor control, and shows clear synergy when combined with PD-1/PD-L1 inhibitors or radiotherapy. Clinical trials have reported mixed outcomes, with meaningful responses observed in selected settings but limited benefit in others. Biomarkers such as TIGIT and CD155 expression, tumor molecular features, and immune landscape characteristics emerged as relevant predictors of response.Conclusion: Anti-TIGIT therapies represent a promising approach for overcoming resistance to ICIs in GI cancers. Nevertheless, biological heterogeneity underscores the need for better patient stratification, predictive biomarkers, and evaluation of safety and toxicity to fully realize the therapeutic potential of TIGIT-targeted strategies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"795-808"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Green synthesis nanoparticles for cancer immunotherapy: current applications and future perspectives. 绿色合成纳米颗粒用于癌症免疫治疗：目前的应用和未来的展望。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-28 DOI: 10.1080/1750743X.2026.2702264

Zahraa AlKhafaje, H Malathi, Aniruddh Dash, Selvakumari J Precilla, Gurjant Singh, Aashna Sinha, Muath Suliman, Aseel Smerat

{"title":"Green synthesis nanoparticles for cancer immunotherapy: current applications and future perspectives.","authors":"Zahraa AlKhafaje, H Malathi, Aniruddh Dash, Selvakumari J Precilla, Gurjant Singh, Aashna Sinha, Muath Suliman, Aseel Smerat","doi":"10.1080/1750743X.2026.2702264","DOIUrl":"10.1080/1750743X.2026.2702264","url":null,"abstract":"Green-synthesized nanoparticles (GSNPs) represent a developing paradigm in cancer immunotherapy, integrating principles of nanotechnology and bio-derived materials. These nanoparticles, produced via eco-friendly biological reductants from plants, microorganisms, or natural polymers, constitute a sustainable class of bioactive biomaterials that can directly interface with immune cells and tissues. Beyond their environmentally conscious synthesis, GSNPs often retain biofunctional moieties from natural sources, providing intrinsic antitumoral and immunomodulatory properties. Such dual behavior enables them to act simultaneously as cytotoxic and immune-activating biomaterials. Relevant literature was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar for studies published between 2010 and 2026 using keywords related to green-synthesized nanoparticles, cancer immunotherapy, immune modulation, and the tumor immune microenvironment. This review comprehensively discusses the synthesis principles of GSNPs, their plant-, microbial-, and biopolymer-mediated fabrication routes, and their immune-modulating and tumoricidal mechanisms of relevance to biomaterial-cell interactions. GSNPs possess tunable physicochemical and biological characteristics that allow activation of macrophages, Th1 polarization, cytokine release, and attenuation of tumor-driven immune suppression. Furthermore, they act synergistically with checkpoint inhibitors or as nanovaccine platforms for antigen delivery. Through apoptosis induction, photothermal ablation, metabolic starvation, and modulation of NF-κB or PI3K/Akt signaling, GSNPs exert direct tumor-killing effects while maintaining biocompatibility.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"777-794"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utility of serum Krebs von den Lungen-6 and surfactant protein D levels for differential diagnosis of immune checkpoint inhibitor-related pneumonitis. 血清Krebs von den Lungen-6和表面活性剂蛋白D水平在免疫检查点抑制剂相关性肺炎鉴别诊断中的应用

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-05 DOI: 10.1080/1750743X.2026.2697671

Shogo Nakai, Masato Karayama, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Satoshi Funayama, Shintaro Ichikawa, Satoshi Goshima, Naoki Inui, Takafumi Suda

{"title":"Utility of serum Krebs von den Lungen-6 and surfactant protein D levels for differential diagnosis of immune checkpoint inhibitor-related pneumonitis.","authors":"Shogo Nakai, Masato Karayama, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Satoshi Funayama, Shintaro Ichikawa, Satoshi Goshima, Naoki Inui, Takafumi Suda","doi":"10.1080/1750743X.2026.2697671","DOIUrl":"10.1080/1750743X.2026.2697671","url":null,"abstract":"Background: Serum Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) are established biomarkers of interstitial lung diseases. However, their utility for differential diagnosis of immune checkpoint inhibitor-related pneumonitis (ICI-P) remains unclear.Methods: This retrospective observational study included cancer patients who newly developed pulmonary diseases and in whom serum KL-6 and/or SP-D levels were measured at disease onset.Results: Among 200 eligible patients, 77 had ICI-P and 123 had other pulmonary diseases (bacterial pneumonia, n = 64; lymphangitic carcinomatosis, n = 42; pulmonary edema, n = 10; radiation pneumonitis, n = 5; and others, n = 2). Serum KL-6 and SP-D levels were significantly higher in patients with ICI-P than in those without (both p < 0.001). The area under the receiver operating characteristic curve was 0.684 for KL-6 and 0.771 for SP-D. KL-6 ≥500 U/mL showed sensitivity and specificity of 0.623 and 0.705, respectively, and SP-D ≥110 ng/mL showed sensitivity and specificity of 0.693 and 0.769, respectively. When both KL-6 ≥500 U/mL and SP-D ≥110 ng/mL, the sensitivity and specificity were 0.480 and 0.907, respectively.Conclusions: KL-6 and SP-D may play a supportive role in the differential diagnosis of ICI-P.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"633-646"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modified Dendritic cells as a therapeutic platform in hematologic malignancies with translational insights from central nervous system tumors. 修饰树突状细胞作为血液系统恶性肿瘤的治疗平台，具有中枢神经系统肿瘤的翻译见解。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-12 DOI: 10.1080/1750743X.2026.2697680

Mahsa Akbari Oryani, Hossein Tabarsa, Ghazaleh Hatamian, Mahboubeh Tajaldini, Hossein Javid, Ali Mehri, Mehdi Karimi-Shahri

{"title":"Modified Dendritic cells as a therapeutic platform in hematologic malignancies with translational insights from central nervous system tumors.","authors":"Mahsa Akbari Oryani, Hossein Tabarsa, Ghazaleh Hatamian, Mahboubeh Tajaldini, Hossein Javid, Ali Mehri, Mehdi Karimi-Shahri","doi":"10.1080/1750743X.2026.2697680","DOIUrl":"10.1080/1750743X.2026.2697680","url":null,"abstract":"Dendritic cell (DC) vaccines elicit specific immune responses capable of precisely eliminating target cells. In recent years, numerous studies have explored the use of DC vaccination for treating hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as various non-leukemic cancers. DCs are utilized primarily through two strategies-in situ and ex vivo (canonical) approaches-to enhance anticancer immunity. The main DC subtypes employed in vaccines for AML and MDS are monocyte-derived DCs and leukemia-derived DCs. Various tumor-associated components have been used as antigen sources to load DCs, including peptides, recombinant proteins, apoptotic leukemic cells, whole tumor cells or lysates, and DCs/DCleu engineered to present a broader antigenic repertoire via RNA electroporation. Innovative strategies have been developed to improve DC vaccine efficacy, including combination therapies with conventional chemotherapy, monospecific or bispecific antibodies, and immune checkpoint inhibitors. Following a decade of challenges, the field has achieved meaningful progress and shows strong potential. This review summarizes recent advances in DC-based immunotherapy with a specific focus on hematologic malignancies, and incorporating comparative translational references from central nervous system tumors most notably glioblastoma to underscore both the common immunologic barriers and the unique mechanistic distinctions.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"695-713"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual legacy of BCG: a century of tuberculosis prevention and the evolving pursuit of trained immunity-based therapies. 卡介苗的双重遗产：一个世纪以来的结核病预防和对训练有素的免疫疗法的不断追求。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-10 DOI: 10.1080/1750743X.2026.2698221

Nazeer Ahmed, Fatima Jawaid, Muhammad Nabeel

{"title":"The dual legacy of BCG: a century of tuberculosis prevention and the evolving pursuit of trained immunity-based therapies.","authors":"Nazeer Ahmed, Fatima Jawaid, Muhammad Nabeel","doi":"10.1080/1750743X.2026.2698221","DOIUrl":"10.1080/1750743X.2026.2698221","url":null,"abstract":"The Bacillus Calmette-Guérin (BCG) vaccine, a live-attenuated derivative of Mycobacterium bovis, has long been central to global tuberculosis prevention. Although it protects well against severe childhood TB, its efficacy against adult pulmonary TB is variable. At the same time, epidemiological and clinical observations suggest that BCG may reduce all-cause mortality and protect against infections beyond TB. Randomised trials have reported lower neonatal all-cause mortality and fewer sepsis-related deaths, supporting the idea of broader immunological benefits. These heterologous effects are proposed to be derived from trained immunity, a form of functional reprogramming of innate immune cells driven by epigenetic and metabolic changes. In some settings, BCG may also induce trained tolerance, leading to a more suppressive immune state, based mainly on animal and in vitro evidence. Clinically, intravesical BCG is an established local immunotherapy for non-muscle-invasive bladder cancer, with current evidence and emerging data suggesting that its effects may extend beyond the bladder through systemic immune training. However, repurposing BCG for other cancers, non-oncological autoimmune diseases, and respiratory tract infections remains established in experimental animal models but is represented with mixed efficacy accompanied by inconclusiveness in human trials and mostly in preclinical or early-phase evidence. Major barriers to translation include strain variability, lack of standardised dosing, uncertain durability, and unresolved long-term safety concerns. Future progress will depend on engineered BCG derivatives, improved delivery systems, rational combination therapies, and well-designed controlled clinical trials.Methodology: Literature was identified through searches of PubMed, Google Scholar, and the Cochrane Library, from database inception to 2026, with a primary focus on studies published between 2011 and 2026.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"743-757"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD137 in cancer therapy - bench to bedside. CD137在癌症治疗中的应用——从实验到临床。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-09 DOI: 10.1080/1750743X.2026.2700925

Kathrine S Rallis, Jessica J Liegel, Alexandra Pommier, M Felicia Ciuculescu, José A Cancelas, John G Gribben, David E Avigan

{"title":"CD137 in cancer therapy - bench to bedside.","authors":"Kathrine S Rallis, Jessica J Liegel, Alexandra Pommier, M Felicia Ciuculescu, José A Cancelas, John G Gribben, David E Avigan","doi":"10.1080/1750743X.2026.2700925","DOIUrl":"10.1080/1750743X.2026.2700925","url":null,"abstract":"CD137 (4-1BB; TNFRSF9) is an inducible costimulatory receptor of the tumor necrosis factor receptor (TNFR) superfamily expressed on activated CD8+ and CD4+ T-cells, natural killer cells, and dendritic cells. By reinforcing T-cell survival, expansion, and memory formation, CD137 has become an attractive target in cancer immunotherapy. Therapeutic strategies include agonistic monoclonal antibodies, bispecific molecules, and adoptive cell therapies enriched for tumor-reactive lymphocytes. Clinical-grade closed bioreactor systems feature a CD137-based enrichment platform utilizing antigen-induced CD137 upregulation to isolate and expand clinically relevant T-cell subsets. Additional innovations such as dendritic cell co-culture systems expressing CD137L and single-cell technologies that characterize highly reactive CD137+ T-cells further enhance precision and potency. Clinical trials of CD137 agonists have shown promising anti-tumor activity; however, hepatotoxicity and variable patient responses remain challenges. Recent work in non-human primate models has clarified the role of CD137 signaling in modulating alloreactivity, with implications for graft-versus-host disease. Despite ongoing barriers - including toxicity, therapeutic resistance, and limited biomarkers - CD137 remains a compelling immunologic target. Future efforts will emphasize context-specific agonism, refined cellular engineering, and multi-omic integration to improve patient selection and therapeutic design. This review summarizes CD137 biology, emerging therapeutic strategies, and translational and clinical directions.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"759-775"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR cellular therapies for acute myeloid leukemia: current landscape and future directions. CAR细胞治疗急性髓性白血病：现状和未来方向。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-19 DOI: 10.1080/1750743X.2026.2689849

Jure Hederih, James Patrick, Isaac Gannon, Alexandros Rampotas, Claire Roddie, Rob Sellar

引用次数: 0

Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis. 探讨变应性鼻炎舌下免疫治疗的全球研究趋势：综合文献计量学分析。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-01 Epub Date: 2026-06-18 DOI: 10.1080/1750743X.2026.2689847

Wenzhe Gu, Zhengjie Shen, Jun Shi, Hao Xu, Hongjun Dong, Daonan Yan, Yunfeng Chu

{"title":"Exploring global research trends in sublingual immunotherapy of allergic rhinitis: a comprehensive bibliometric analysis.","authors":"Wenzhe Gu, Zhengjie Shen, Jun Shi, Hao Xu, Hongjun Dong, Daonan Yan, Yunfeng Chu","doi":"10.1080/1750743X.2026.2689847","DOIUrl":"10.1080/1750743X.2026.2689847","url":null,"abstract":"Aims: Sublingual immunotherapy (SLIT) is a well-established, safe, and patient-friendly treatment for allergic rhinitis. This study aims to provide a comprehensive bibliometric analysis of global research trends and emerging hotspots in SLIT for allergic rhinitis.Methods: Relevant publications were sourced from the Web of Science Core Collection (1993-2024). VOSviewer, CiteSpace, and the R \"bibliometrix\" package were used to visualize research collaborations, leading contributors, and thematic developments.Results: This analysis of 696 publications on SLIT for allergic rhinitis reveals a dynamic, collaborative field. The USA, China, and Italy led production, with the University of Genoa as the top institution. Research is organized into six clusters: immunological mechanisms, clinical efficacy, epidemiology/guidelines, pediatric research, disease classification, and real-world evidence.The focus has evolved over two decades from initial clinical efficacy studies toward understanding underlying immune mechanisms (highlighted by recent keyword bursts like \"dendritic cells\"), biomarker discovery, and specialized pediatric applications. There is also a strengthened emphasis on long-term management and real-world effectiveness.Conclusion: SLIT research is diversifying, marked by a growing emphasis on immunology, personalized and pediatric approaches, and practical outcomes, providing a robust foundation for optimizing future therapy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"547-558"},"PeriodicalIF":2.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13348961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0